key: cord-0766728-473aq14u
authors: Brandão, Pedro Renato P.; Grippe, Talyta C.; Pereira, Danilo A.; Munhoz, Renato P.; Cardoso, Francisco
title: New-Onset Movement Disorders Associated with COVID-19
date: 2021-07-08
journal: Tremor and other hyperkinetic movements
DOI: 10.5334/tohm.595
sha: 7b054a2e4bb00b43ede9b44c1047f0e005b7a8fb
doc_id: 766728
cord_uid: 473aq14u

INTRODUCTION: Movement disorders are increasingly described in hospitalized and milder cases of SARS-CoV-2 infection, despite a very low prevalence compared to the total patients. METHODS: We reviewed the scientific literature published in English, spanning from the initial descriptions of COVID-19 until January 25, 2021, in the PubMed/MEDLINE database. RESULTS: We identified 93 new-onset movement disorders cases (44 articles) from 200 papers screened in the database or reference lists. Myoclonus was present in 63.4% (n = 59), ataxia in 38.7% (n = 36), action/postural tremor in 10.8% (n = 10), rigid-akinetic syndrome in 5.38% (n = 5), oculomotor abnormalities in 20.4% (n = 19), catatonia in 2.1% (n = 2), dystonia in 1.1% (n = 1), chorea in 1.1% (n = 1), functional (psychogenic) movement disorders in 3.2% (n = 3) of the reported COVID-19 cases with any movement disorder. Encephalopathy was a common association (n = 37, 39.78%). DISCUSSION: Comprehensive neurophysiological, clinical, and neuroimaging descriptions of movement disorders in the setting of SARS-CoV-2 infection are still lacking, and their pathophysiology may be related to inflammatory, postinfectious, or even indirect mechanisms not specific to SARS-CoV-2, such as ischemic-hypoxic brain insults, drug effects, sepsis, kidney failure. Cortical/subcortical myoclonus, which the cited secondary mechanisms can largely cause, seems to be the most common hyperkinetic abnormal movement, and it might occur in association with encephalopathy and ataxia. CONCLUSION: This brief review contributes to the clinical description of SARS-CoV-2 potential neurological manifestations, assisting clinical neurologists in identifying features of these uncommon syndromes as a part of COVID-19 symptomatology. HIGHLIGHTS: – Movement disorders are probably uncommon neurological manifestations in SARS-CoV-2 infection; – Myoclonus is the most reported movement disorder associated with COVID-19, its clinical complications or pharmacological management; – The pathophysiology is yet not well-understood but can include systemic inflammation, autoimmune mechanisms, or hypoxia.

Coronavirus disease 2019 (COVID-19) has been associated with various neurological symptoms [1, 2] . Numerous putative dissemination mechanisms of the central nervous system (CNS) were hypothesized, including direct retrograde spread through the olfactory nerve via the transcribiform pathway or hematogenous spread via the blood-brain barrier. The neuronal damage could happen through different but not mutually exclusive mechanisms, including direct viral insult, cytokine release syndrome, hypoxia, immune-mediated neuroinflammation (post or para-infectious), coagulopathy, and endothelial dysfunction syndrome [1] . Headache, altered mental status (encephalopathy), chemosensory dysfunction (anosmia, ageusia), cerebrovascular events, and myalgia seem to be the most typical neurological manifestations [2] . However, the description of the isolated virus in the cerebrospinal fluid (CSF) is seemingly rare, suggesting that direct viral meningoencephalitis is not usual.

Movement disorders are increasingly being described not only among hospitalized patients but also in milder cases of SARS-CoV-2 infection, despite a possible very low prevalence in comparison to the total cases [3, 4] . This study aims to summarize and describe, through a systematic procedure, relevant clinical and ancillary exam findings in patients with new-onset movement disorders associated with COVID-19.

We first searched the PubMed/MEDLINE database for relevant literature published in the English language, between the initial descriptions of COVID-19 (December 31, 2019) and January 25, 2021, using the search terms "COVID-19" OR "SARS-CoV-2" OR "Coronavirus Disease 2019" OR "2019 n-CoV" OR "2019 Novel Coronavirus" AND ("movement disorders" OR "myoclonus" OR "ataxia" OR "parkinsonism" OR "Parkinson's disease" OR "chorea" OR "dystonia" OR "myoclonus" OR "catatonia" OR "tremor")" as search terms (n = 332). We added filters for Case Reports, Classical Articles, Clinical Studies, Clinical Trial, Comparative Studies, Original Journal Articles, Letters, Observational Studies, Human Species and identified 296 records for screening (titles/ abstracts). We conducted a prospection in the reference list of selected papers and other sources, identifying additional 19 items. After excluding 115 records with abstracts and titles irrelevant to this study's scope, we screened 200 records for eligibility. We evaluated 81 full-text papers for eligibility after withdrawing 119 articles for the following reasons: they were not written in English or were focused on social or healthcare impact of COVID-19 in patients already diagnosed with a movement disorder, dealt with aggravation of pre-existing movement disorders, telemedicine management strategies, or were listed as review/hypothesis/opinion articles ( Figure   1 ). A total of 44 studies were included for qualitative and quantitative synthesis as representative of neurological descriptions of new-onset movement disorders in the context of SARS-CoV-2 infection.

Two authors (PB and TG) collected data independently, using a predefined protocol. One of the five authors (PB) checked the extracted data, and discrepancies were resolved by consensus between the two data collectors. Variables of interest included counts for single or combined movement disorders (myoclonus, dystonia, ataxia, parkinsonism, chorea, catatonia, action/postural tremors, oculomotor disturbances), associated clinical features (encephalopathy, stroke), summaries of ancillary exam results (FDG-PET, MRI/CT, ENMG, CSF, and EEG). The attempted treatment options (symptomatic treatment or immunotherapy, such as intravenous immunoglobulin -IVIg, steroids) were also counted. Clinical characteristics were quantified as case counts and ratios of case counts to total cases. Symptoms not initially reported in individual studies were considered absent (zero) rather than missing (NA).

Descriptive statistical analysis was performed using Wizard v2.0.4 (Evan Miller, 2020, https://www.wizardmac. com) and R v4.0.4 (https://www.R-project.org/). A world map including the reported cases was generated using Datawrapper (https://app.datawrapper.de). The "brms"

-Movement disorders are probably uncommon neurological manifestations in SARS-CoV-2 infection; -Myoclonus is the most reported movement disorder associated with COVID-19, its clinical complications or pharmacological management; -The pathophysiology is yet not well-understood but can include systemic inflammation, autoimmune mechanisms, or hypoxia.

R package was used to obtain the parameter values' Bayesian posterior distribution [5] . "Brms" uses the logitlink to convert the linear predictor zi (zero-inflated) to a probability. The logit-link accepts values between 0 and 1 and returns values on the real line. As a result, it enables the conversion of probabilities to linear predictors. Samples were drawn using No-U-Turn-Sampler (NUTS) sampling, the default algorithm used by the Stan program [6] . Rhat was used as a potential scale reduction factor on split chains (at convergence, Rhat = 1). We fit the model using four Hamiltonian Monte-Carlo (HMC) chains. We used Jeffrey's beta (0.5, 0.5) as the prior argument for zi rather than the default "flat" beta (1, 1) used by "brms". The intercept parameter prior was normal (0, 10). The Bayesian plot was created using the "bayesplot" R package (https://mc-stan.

org/bayesplot/) [7] . Using counts as the measure of movement disorders frequency (main variables extracted from the articles), we performed an unsupervised grouping procedure (clustering) to separate and observe co-occurrence between the symptoms in the reported articles. The "NbClust" R package was used to determine the optimal number of clusters [8] . It provides 30 indices for that task and proposes the best clustering scheme by varying all combinations of several clusters, distance measures, and clustering methods (Supplementary Figure 1) . We then employed a random forest (RF) clustering strategy to avoid variable transformation (e.g., categorical features). By forming two unique groups (as determined by the NbClust's method), RF clustering separated the original data from the virtual clusters. The similarity between two data instances was assessed using the proportion of trees that shared a single leaf node. The PAM (partition around medoids) technique [9] was used to assign each object to the closest medoid (object with the smallest dissimilarity) as a step to create the clusters.

Forty-four initial papers were ultimately chosen from a total of 81 full-text articles that were evaluated for eligibility, including a total of 93 specific cases of movement disorders caused by or acutely linked to SARS-CoV-2 infection or its pharmacological treatment attempts. Table 1 summarizes these cases and publications. Coronavirus" AND ("movement disorders" OR "myoclonus" OR "ataxia" OR "parkinsonism" OR "Parkinson's disease" OR "chorea" OR "dystonia" OR "myoclonus" OR "catatonia" OR "tremor"). The cases came generally from regions where COVID-19 epidemics were on course. A proportion of 57.0% of the cases were reported in Europe (n = 53), 26.9% in the Americas (n = 25), 15% in Asia (n = 14), 1% in Oceania (n = 1). Most reported cases came from France (n = 17, 18.3%), United States (n = 17, 18.3%), Spain (n = 16, 17.2%), followed by Brazil (n = 8, 8.6%), Iran (n = 8, 8.6%) Germany (n = 8, 8.6%), Italy (n = 7, 7.5%), United Kingdom (n = 3, 3.2%) and China (n = 3, 3.2%). Japan, Netherlands, Israel, New Zealand, Philippines, and Belgium reported 1 case each (1.1% each), as represented in Figure 2 .

The major findings are depicted in Figure 3 as Bayesian binomial posterior proportions. Table 1 summarizes the clinical and ancillary exam data from each original study to serve as a simple reference guide for physicians and researchers.

Of the 93 movement disorder cases identified in the literature search [3, 4, , myoclonus was present (Figure 2) . Encephalopathy was a frequent association (n = 37, 39.8%), and stroke was detected in a minority of cases (n = 5, 5.4%).

As previously stated, the most prevalent movement disorder was myoclonus [4, 11, 13-18, 27, 28, 30-34, 39, 41, 43, 47, 48, 50-52] , which often occurred in conjunction with encephalopathy/delirium. More than a third of the sample had ataxia [16-23, 27, 29, 32-34, 37-40, 43, 46, 50, 51] , which often co-occurred with myoclonus. Oculomotor symptoms, such as saccadic oscillations (opsoclonus, ocular flutter), have also been documented and were often associated with ataxia [13, 14, 16, 18, 19, 27, 29, 41, 43, 47, 50, 51] . Among the cases presenting with ataxia, a few were associated with acute polyradiculopathy/neuropathy (sensory ataxia, in the context of Miller-Fisher syndrome) [19, 20, 37] . In contrast, others presented cerebellar ataxia in a cerebellitis context [23] or unremarkable MRI and CSF examinations [16-18, 21, 25, 27] .

Not surprisingly, confusional or encephalopathic states were highly prevalent in patients with action and stimulussensitive myoclonus. Myoclonus is a frequent involuntary movement in critically ill patients triggered or aggravated by several different drugs or by metabolic or hypoxia-related brain dysfunction [53] . Encephalopathy and delirium are very prevalent in critical care [54] , and the reviewed sample has a significant proportion of hospitalized and critical patients. Three cases of new-onset rigid-akinetic parkinsonism were described in detail [10, 11, 26] , one of which presented with encephalopathy and generalized myoclonus [11] , two of which were preceded only by a mild respiratory syndrome [10, 26] .

Some de novo movement disorders were presumably drug-induced: two serotonin syndrome cases possibly related to lopinavir/ritonavir combined with drugs with serotonergic properties, and three tardive syndrome cases (described as rigid-akinetic syndromes combined to orobuccal stereotypies) [13] . Due to incomplete information, it was not feasible to establish a causal link between myoclonus and drug administration in critically ill mechanically ventilated patients, in whom sedative agents, especially opioids, or antipsychotic medications, may have contributed to myoclonus.

Neuroimaging (Brain MRI or head CT) findings were reported in 82.8% (n = 77) of the 93 cases. About two-thirds (n = 56, 72.7%) of these cases demonstrated normal or non-related findings (chronic findings, such as white matter small vessel disorder). Five patients had cerebral microbleeds (6.5%). Stroke was disclosed in 4 cases (5.2%). Post-contrast focal enhancement or edema was seen in 10 cases (12.9%). Some of these observations are described in greater detail below: Gadolinium (Gd) enhancement of the oculomotor nerve (in a Miller-Fisher syndrome case, 1/77, 1.3%), cerebellar edema with Gd enhancement (1/77, 1.3%), cortical or brainstem hypoxic-ischemic lesions (2/77, 2.6%), pachymeningeal enhancement (1/77, 1.3%), acute leukoencephalitis (3/77, 3.9%), splenium DWI hyperintensity (1/77, 1.3%), splenium microbleeds (1/77, 1.3%), fornix edema (1/77, 1.3%), orbitofrontal hyperintensity (1/77, 1.3%), middle cerebral artery stroke (2, 2.6%), and multiple focal enhancing lesions in putamen and cerebellum (1, 1.3%).

FDG-PET scan was performed in five patients, as described below. It showed normal glucose metabolism in a case with parkinsonism [10] . Two of these five scanned patients had myoclonus and ataxia [34, 43] , one had ataxia and other cerebellar signs [43] , and one had orofacial myoclonus [47] . FDG-PET revealed hypermetabolic cerebellum in all four cases: two also had hypermetabolism in the basal ganglia, while the other three had cortical hypometabolism.

The three parkinsonism cases had confirmed nigrostriatal denervation by functional dopaminergic imaging, using 18F-DOPA PET, DAT-Scan, or TRODAT-1 SPECT.

For 48.4% (n = 45) of the examined cases, cerebrospinal fluid (CSF) analysis was available. About 73.3 % (n = 33) of the patients had a normal cell count, while 26.7% (n = 12) had mild-to-moderate pleocytosis. We observed that 51% (n = 23) of patients had normal CSF protein levels, while 49.9% (n = 22) had slightly elevated protein levels.

Antineuronal paraneoplastic antibodies (Abs) were not detected in any of the cases when a standardized Abs panel was tested (n = 9). Antibodies against Purkinje cells, striatal, and hippocampal neurons were observed in one patient with subacute cerebellar syndrome and myoclonus utilizing tissue immunostaining [34] . Franke et al. used indirect immunofluorescence to screen antibodies against novel CNS epitopes in unfixed mouse brain sections. They found staining associated with vessel endothelium, astrocytic proteins, and neuropil of basal ganglia, hippocampus, or olfactory bulb [47] . SARS-CoV-2 RT-qPCR positivity in CSF samples appears to be uncommon: it was detected in only one case of cerebellitis [23] .

EEG findings were available in 29% (n = 27) of the cases. Of these, 59.3% (n = 16) had background slowing, while 33.3% (n = 9) had normal results. In one case, lateralized periodic discharges were observed in association with diaphragmatic myoclonus [31] , while in another, frontal spikes were observed [21] . Two studies (three cases) used neurophysiological measures to characterize the possible CNS topographic origin of myoclonus [15, 31] , using a combination of EEG and EMG or jerk-locked registers. Two of the three cases had cortical/subcortical origin, and one, a subcortical source.

In 39.8% of the cases (n = 37), the information about treatment attempts was incomplete or missing. There was immunotherapy with oral/intravenous steroids (n = 21, 37.5%). In 11 cases, the corticosteroid therapy targeted the movement disorder; in 5 cases, it targeted COVID-19related inflammatory reaction and, in 4 cases, the target was not clear. Immunoglobulin (IVIg) was used in 32.14% (n = 18) of the reported cases with available treatment information (n = 56). In all of these cases, IVIg therapy was targeting the movement disorder. Plasma exchange was tried in one case. Immunotherapy was used primarily in inpatient settings, but cases ranged from mild to critically ill in mechanical ventilation.

Antiepileptic drugs and benzodiazepines such as clonazepam (n = 17), levetiracetam (n = 16), valproic acid (n = 10), and lorazepam (n = 5) seemed to be favored for symptomatic care, mostly for the myoclonus presentation. Additionally, dexmedetomidine (n = 5), ketamine (n = 1), primidone (n = 1), and midazolam (n = 1) were used in treatment attempts.

In this analysis, we generated a regression using Bayesian zero-inflated Poisson (ZIP), a model for counts-based datasets with an excess of zero-valued data in the dependent variable (assuming a constant zero-inflation probability across observations). A value of "zero" indicates that nothing occurred, which may be because the events' rate is low or because the process that causes events failed to start.

Within the data extracted from the sample of COVID-19 associated with new-onset movement disorders, myoclonus was associated with normal neuroimaging results (head CT or brain MRI) and encephalopathy (left side of Figure 4) 

Cluster analysis was utilized to infer movement disorders syndromic grouping from the reviewed articles. According to a seven indices ensembling method (NbClust), we found two as the optimal number of clusters. The PAM method then evaluated dissimilarity among objects. By assembling two unique groups, the random forest (RF) clustering approach [53] identified 36 articles with a higher proportion of myoclonus reports associated with encephalopathy and eight articles with a higher proportion of myoclonus connected with ataxia or oculomotor disturbances.

We interpreted these findings as suggestive of at least two myoclonus-associated syndromes that might occur in COVID-19: (1) a syndrome that associates myoclonus and encephalopathic state (which, we speculate, may relate to with broader brain dysfunction and neuronal hyperexcitability due to clinical complications in critical care or pharmacological interactions); and (2) a post-viral syndrome with an autoimmune origin that links oculomotor disturbances, ataxia, and myoclonus, resembling an opsoclonus-myoclonus-ataxia syndrome.

Notably, myoclonus is the most frequently identified movement disorder associated with COVID-19. Myoclonus is defined as a sudden, brief involuntary muscle contraction (positive myoclonus) or abrupt cessation of muscle contraction (negative myoclonus) [55] . It occurs in a wide variety of etiologies, including post anoxic (Lance-Adams syndrome), metabolic (liver and renal failure, electrolyte imbalances), toxic, drug-induced (opioids, levodopa, antidepressants, quinolones, antiepileptic drugs), paraneoplastic, autoimmune (as in opsoclonus-myoclonusataxia syndrome), infectious (or postinfectious), genetic and neurodegenerative disorders. Additionally, it can be categorized into cortical, subcortical, spinal, or peripheral myoclonus based on its underlying neurophysiology (CNS source) [55] .

It is critical to emphasize that in cases stated to be associated with COVID-19, several factors can contribute to the incidence of myoclonus: kidney failure, usage of provoking drugs in the context of intensive care, such as antibiotics, fentanyl, propofol, or phenytoin, as well as prolonged and sustained hypoxia [33, 56] .

Muccioli et al. conducted a comprehensive clinical and paraclinical assessment, suggesting that myoclonus could have a subcortical origin [30] . Interestingly, a proportion of myoclonus cases seemed to present in a delayedonset compared to the infectious syndrome [28] [29] [30] ; concurrent ataxic manifestations were not unusual. Recent publications have emphasized the description of opsoclonus-myoclonus-ataxia (in its complete or incomplete clinical syndrome) and included clinical improvement after IVIg therapy [27, 50, 51] . Myoclonic jerks were usually symptomatically treated with antiepileptic drugs (levetiracetam and valproate) and benzodiazepines (clonazepam, lorazepam).

According to a published comment on this topic, myoclonus's underlying pathophysiology in COVID-19 may have a post-hypoxic or a postinfectious nature [56] . Although a putative physiopathology involving antigenic cross-reactivity with neuronal proteins from the brainstem or cerebellum remains hypothetical, an interesting case series from Germany provides initial support for this thesis [47] . The CNS's postulated role in the production of myoclonus could be attributed to brainstem hyperexcitability or even lack of cerebellar inhibitory output [56] . Normal structural neuroimaging findings are consistent with the hypothesis that some of these movement disorders may be mediated by post-viral immune processes rather than structural lesions.

In a small number of cases, the CSF profile was examined. A few patients presented with mild mononuclear pleocytosis. The most frequently observed phenotype was normal cell count, mild hyperproteinemia, and normal glucose levels. The rise in CSF protein levels may be caused by blood-CSF barrier disruption, intrathecal immunoglobulin synthesis, or even be secondary to pre-existing medical comorbidities. However, further research is needed to ascertain an intrathecal immunological or parainfectious reaction, using techniques such as Reiber diagram and comprehensive autoantibodies analysis [57] .

FDG-PET results provide some insights: they indicate that in some cases, presenting as movement disorders, an active ongoing metabolic process involving primarily the cerebellum and basal ganglia is implicated [34] . Additionally, they support a subcortical origin for myoclonus in COVID-19. Further research is required to validate this idea and better understand these metabolic PET patterns [32] .

Parkinsonism related to SARS-CoV2 seems to be a very unusual manifestation. Brundin et al. hypothesized that parkinsonism links with COVID-19 through the following mechanisms: (a) vascular insults to the nigrostriatal system (if with imaging compatible with stroke); (b) neuroinflammation triggered by systemic inflammation; (c) neuroinvasion and direct neuronal damage by the virus, that could gain access to the brain via olfactory nerve or gastrointestinal/respiratory tract via the vagus nerve [58] .

The three initial cases linking COVID-19 and parkinsonism had acutely developed severe symptoms, which could suggest a direct link between nigrostriatal damage and SARS-CoV-2 but are not indeed able to prove a causal relationship between COVID-19 and Parkinson's disease [10, 11, 26] . Prodromal or presymptomatic PD could be unmasked when individuals are acutely ill. We could not reject that this might be the case in the reported patients with "acute onset" parkinsonism. Cohort studies of COVID-19 persistent anosmic cases, followed up for years, will help to disentangle such a link.

Serotonin syndrome was documented in two patients due to combined drugs for COVID-19 and other comorbidities [11] . Due to the high prevalence of psychiatric disorders, it is critical to consider this a possible differential diagnosis when myoclonus is between the clinical signs, as it is a treatable condition.

Neuropathological assessment of COVID-19 came initially from small case series that described hypoxic injury, blood-brain barrier breakdown, microscopic infarcts, hemorrhagic and demyelinating white matter lesions, and a scarcity of RT-qPCR positivity in brain samples [59] [60] [61] . Microglial activation, microglial nodules, and neuronophagia have also been described [62] . To our knowledge, no neuropathological study has been conducted to precisely examine the relationship between SARS-CoV-2 and movement disorders during acute or post-acute infection.

Our study has several limitations: heterogeneity of the sample (with a predominance of case reports and case series), a bias towards hospitalized patients with severe COVID-19 (requiring consultation with a neurology specialist), heterogeneity of available information, lack of a control group (composed of patients with similar infectious conditions, for example) for prevalence rates comparison. Even with a standardized data collection protocol, we could not address the issue of missing information. Thus, these findings produce hypotheses for future research rather than lead to causal inferences or overinterpretation.

Movement disorders were early (in the pandemic's course) predicted to manifest in COVID-19 patients. However, they represent uncommon or underreported phenomena concerning the infected population as a whole [63] . This brief study contributes to the clinical scenario of SARS-CoV-2. It guides general practicing neurologists to the potential identification of these uncommon movement disorders syndromes as part of COVID-19 symptomatology or a consequence of its pharmacological management or clinical complications. Myoclonus and ataxia deserve special attention in upcoming studies: these two manifestations were the most prevalent in the reviewed data, could appear in combination, and may have an immune origin. The direct link between movement disorders and SARS-CoV-2 (and its underlying mechanisms) will be established or disproved in still lacking comprehensive neurophysiological, molecular, pathological, and neuroimaging studies with large samples.

The additional file for this article can be found as follows: 

The authors have no competing interests to declare.

PB and TG assisted in the research design, data analysis, and manuscript writing; DP, RM, and FC assisted in the data analysis and manuscript writing. The published version of the manuscript was read and approved by all authors.

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease

Neurological complications in patients with SARS-CoV-2 infection: A systematic review

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital

brms: An R Package for Bayesian Multilevel Models Using Stan

Stan Modeling Language Users Guide and Reference Manual, 2.26

Visualization in Bayesian workflow

NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set

Faster k-Medoids Clustering: Improving the PAM, CLARA, and CLARANS Algorithms

Coronavirus Disease 2019 and Parkinsonism: A Non⁸ post⁸ encephalitic Case

Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection

Functional movement disorders in a patient with COVID-19

Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir

Movement disorders as a new neurological clinical picture in severe SARS⁸ CoV⁸ 2 infection

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection

Myoclonus and Cerebellar Ataxia Following COVID⁸ -19

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

COVID-19-Associated Miller Fisher Syndrome: MRI Findings

Onset of COVID-19 with impaired consciousness and ataxia: a case report

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

A First Case of Acute Cerebellitis Associated with Coronavirus Disease (COVID-19): a Case Report and Literature Review

New onset neurologic events in people with COVID-19 in 3 regions in China

A Case Report of Coronavirus Disease 2019 Presenting with Tremors and Gait Disturbance. Clinical Practice and Cases in Emergency Medicine

A case of probable Parkinson's disease after SARS-CoV-2 infection

Opsoclonus Myoclonus Ataxia Syndrome Related to the Novel Coronavirus (COVID-19)

Post⁸ Hypoxic Myoclonus after COVID-19 Infection Recovery

Abnormal Saccadic Oscillations Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Encephalopathy and Ataxia

Subcortical Myoclonus in Coronavirus Disease 2019: Comprehensive Evaluation of a Patient

Diaphragmatic myoclonus due to SARS-CoV-2 infection

Reversible Myoclonus⁸ Ataxia as a Postinfectious Manifestation of COVID-⁸ 19

Myoclonus in Patients With Coronavirus Disease 2019: A Multicenter Case Series

Autoimmune Encephalitis Concomitant with SARS-CoV-2 Infection: Insight from 18 F-FDG PET Imaging and Neuronal Autoantibodies

COVID-⁸ 19 encephalopathy masquerading as substance withdrawal

A Case Report of Acute Motor and Sensory Polyneuropathy as the Presenting Symptom of SARS-CoV-2. Clinical Practice and Cases in Emergency Medicine

Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID-19)

COVID-19 presenting with ophthalmoparesis from cranial nerve palsy

Cytokine release syndrome⁸ associated encephalopathy in patients with COVID-⁸ 19

COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion

Postinfectious brainstem encephalitis associated with SARS-CoV-2

Steroid⁸ Responsive Encephalitis in Coronavirus Disease

COVID⁸ -19 ⁸ related encephalopathy: a case series with brain FDG⁸ positron⁸ emission tomography/computed tomography findings

A Case of Catatonia in a Man With COVID-19

Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2-Related Encephalitis: The ENCOVID Multicenter Study. The Journal of Infectious Diseases

Acute Cerebellar Ataxia in COVID-19 Infection: A Case Report

High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain, Behavior, and Immunity

Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia

Life-Threatening Catatonia Associated With Coronavirus Disease

Opsoclonusmyoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature

COPYRIGHT: © 2021 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium

Tremor and Other Hyperkinetic Movements is a peer-reviewed open access journal published by

Neurologic manifestations in hospitalized patients with COVID-19

Myoclonus in the critically ill: Diagnosis, management, and clinical impact

Incidence and Prevalence of Delirium Subtypes in an Adult ICU

A novel diagnostic approach to patients with myoclonus

Myoclonus and COVID⁸ -19: A Challenge for the Present, a Lesson for the Future

Cerebrospinal fluid data compilation and knowledge-based interpretation of bacterial, viral, parasitic, oncological, chronic inflammatory and demyelinating diseases

Is COVID-19 a Perfect Storm for Parkinson's Disease?

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

Neuropathological Features of COVID-19

Early evidence of pronounced brain involvement in fatal COVID-19 outcomes

COVID-19 neuropathology at Columbia University Irving Medical Center/ New York Presbyterian Hospital

Movement Disorders in COVID-19: Whither Art Thou? Tremor and Other Hyperkinetic Movements